A human expression system based on HEK293 for the stable production of recombinant erythropoietin

Система экспрессии на основе клеток HEK293 для стабильного получения рекомбинантного эритропоэтина
Christine Lin Chin, Justin B. Goh, Harini Srinivasan, Kaiwen Ivy Liu, Gowher Ali, Raghuvaran Shanmugam, Hsueh Lee Lim, Matthew S. Choo, Wen Qin Tang, Andy Hee‐Meng Tan, Terry Nguyen‐Khuong, Meng How Tan, Say Kong Ng
2019-11-14

CRISPR-Cas9 GLUL knockoutHEK293 expression systemfed-batch bioreactorhuman N-glycosylationrecombinant erythropoietin
Mammalian host cell lines are the preferred expression systems for the manufacture of complex therapeutics and recombinant proteins. However, the most utilized mammalian host systems, namely Chinese hamster ovary (CHO), Sp2/0 and NS0 mouse myeloma cells, can produce glycoproteins with non-human glycans that may potentially illicit immunogenic responses. Hence, we developed a fully human expression system based on HEK293 cells for the stable and high titer production of recombinant proteins by first knocking out GLUL (encoding glutamine synthetase) using CRISPR-Cas9 system. Expression vectors using human GLUL as selection marker were then generated, with recombinant human erythropoietin (EPO) as our model protein. Selection was performed using methionine sulfoximine (MSX) to select for high EPO expression cells. EPO production of up to 92700 U/mL of EPO as analyzed by ELISA or 696 mg/L by densitometry was demonstrated in a 2 L stirred-tank fed batch bioreactor. Mass spectrometry analysis revealed that N-glycosylation of the produced EPO was similar to endogenous human proteins and non-human glycan epitopes were not detected. Collectively, our results highlight the use of a human cellular expression system for the high titer and xenogeneic-free production of EPO and possibly other complex recombinant proteins.
1
A fully human recombinant-protein expression system was developed using HEK293 cells with CRISPR-Cas9 knockout of GLUL.
2
Human GLUL-based expression vectors and methionine sulfoximine selection enabled stable, high-level production of recombinant erythropoietin.
3
In a 2 L stirred-tank fed-batch bioreactor, EPO production reached up to 92,700 U/mL by ELISA or 696 mg/L by densitometry.
4
Produced EPO displayed N-glycosylation similar to endogenous human proteins, with no detected non-human glycan epitopes.
5
The HEK293 system enables high-titer, xenogeneic-free production of EPO and potentially other complex recombinant proteins.

HEK293-based human expression system for stable recombinant erythropoietin production

High-titer production and human-like, xenogeneic-free N-glycosylation of recombinant EPO

Publication Details
Publication Date
2019-11-14
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Christine Lin Chin
Justin B. Goh
Harini Srinivasan
Kaiwen Ivy Liu
Gowher Ali
Raghuvaran Shanmugam
Hsueh Lee Lim
Matthew S. Choo
Wen Qin Tang
Andy Hee‐Meng Tan
Terry Nguyen‐Khuong
Meng How Tan
Say Kong Ng
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%